Related references
Note: Only part of the references are listed.Updates on apolipoprotein CIII: fulfilling promise as a therapeutic target for hypertriglyceridemia and cardiovascular disease
Chunyu Zheng
CURRENT OPINION IN LIPIDOLOGY (2014)
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Anders Berg Jorgensen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
Jacy Crosby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans
Mark J. Graham et al.
CIRCULATION RESEARCH (2013)
Response to Comment on: Korpos et al. The Peri-islet Basement Membrane, a Barrier to Infiltrating Leukocytes in Type 1 Diabetes in Mouse and Human. Diabetes 2013;62:531–542
Éva Korpos et al.
DIABETES (2013)
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
D. Gaudet et al.
GENE THERAPY (2013)
Antisense Technology: An Emerging Platform for Cardiovascular Disease Therapeutics
Richard G. Lee et al.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH (2013)
Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
Zemin Yao et al.
CURRENT OPINION IN LIPIDOLOGY (2012)
Clinical Lipidology Roundtable Discussion Severe hypertriglyceridemia
W. Virgil Brown et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2012)
Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia
R. P. Surendran et al.
JOURNAL OF INTERNAL MEDICINE (2012)
Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart Disease
Carlos O. Mendivil et al.
CIRCULATION (2011)
ESC/EAS GUIDELINES ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY (2011)
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
M. John Chapman et al.
EUROPEAN HEART JOURNAL (2011)
Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population: National Health and Nutrition Examination Survey 2005-2008
Jennifer B. Christian et al.
JOURNAL OF CARDIOVASCULAR MEDICINE (2011)
Etiology and risk of lactescent plasma and severe hypertriglyceridemia
Karine Tremblay et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2011)
Thematic Review Series: Genetics of Human Lipid Diseases Genetic determinants of plasma triglycerides
Christopher T. Johansen et al.
JOURNAL OF LIPID RESEARCH (2011)
ESC/EAS Guidelines for the management of dyslipidaemias
Zeljko Reiner et al.
EUROPEAN HEART JOURNAL (2011)
Apolipoprotein C3 Gene Variants in Nonalcoholic Fatty Liver Disease
Kitt Falk Petersen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Apolipoprotein C-III: understanding an emerging cardiovascular risk factor
Esther M. M. Ooi et al.
CLINICAL SCIENCE (2008)
A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection
Toni I. Pollin et al.
SCIENCE (2008)
Lipoprotein genotype and conserved pathway for exceptional longevity in humans
G Atzmon et al.
PLOS BIOLOGY (2006)
Share Paper
